Full-Time

Associate Director Medical Science Liaison

Women's Health

Posted on 5/7/2026

Viatris

Viatris

10,001+ employees

Global pharma selling generics and biosimilars

Compensation Overview

$95k - $193k/yr

Remote in USA

Remote

Preferred locations: CA, TX, NV. Extensive travel (50-80%), may include overnight or weekend travel.

Category
Biology & Biotech (1)
Required Skills
Veeva
Data Analysis
Requirements
  • Minimum of 5 years of experience in the pharmaceutical, biotech or clinical (e.g., hospital setting/patient care) industry. Advanced degree (MD, PhD, PharmD) required. Experience in OB/GYN is required. Must possess knowledge of the US Women’s Health Medical Science Liaison (MSL) roles and responsibilities, clinical trials, relevant therapeutic areas, understand all applicable Standard Operating Procedures (SOPs), the Standards for Interactions with U.S. Healthcare Providers, Federal and State promotional laws and regulations, the PhRMA Code, ACCME Standards, and the Code of Business Conduct and Ethics.
  • Must possess ability to effectively communicate, develop, and manage collaborative relationships with KOLs and other medical professionals, external academic institutions and Patient Advocacy Groups. Strong analytic and organizational skills in managing, interpreting, and presenting clinical data. Ability to actively listen for insights stated directly or indirectly by stakeholders, and draw implications for Viatris. Driven by personal accountability & high levels of performance. Ability to set and accomplish compelling goals both individually and in a team setting. Motivated to overcome challenges, seek out opportunities, and develop both personally and professionally. Comfortable with change. Embraces the principles of Diversity, Equity & Inclusion (DEI).
  • Ability to read and interpret comprehensive and intricate research documents. Ability to write scientific reports and technical correspondence. Ability to work with executives and communicate abstract concepts. Ability to present to a high level of the organization and groups outside of the organization.
  • Ability to perform computations such as percentages, ratios, and rates, as well as perform statistical analysis. Ability to draw and interpret graphical data. Ability to understand pharmaceutical calculations is preferred.
  • Ability to solve problems with a variety of concrete variables through semi-standardized solutions that require some ingenuity and analysis. Ability to draw inferences and follow prescribed and detailed procedures to solve moderately complex problems.
  • Position functions semi-autonomously with no direct supervisory responsibilities. Position reports to US Women’s Health MSL Team Lead.
  • US Remote. Extensive travel (50% - 80% of time, which may change) is a requirement; may include overnight stays and/or weekend travel; also leverage remote participation. Geographical territory may change over time.
  • Preferred locations would be CA, TX, NV.
Responsibilities
  • 100% compliant with all Company policies & procedures
  • Learning & Growth (eg, Improve skills & abilities, Develop medical expertise, Develop strategic leadership)
  • Operational Excellence (eg, Improve operational efficiency, Improve operational effectiveness, Align medical activities with overarching company strategy)
  • KOL Relationship Management (eg, Understand KOL medical education needs, Understand competitor medical affairs educational offerings, Align KOL selection with overarching company strategy)
  • Innovation (eg, Understand medical innovation, Uniquely meet HCP innovation-based education needs, Increase use of innovative education materials)
  • Engage in non-promotional, truthful, evidenced-based, and non-misleading communications with KOLs/HCPs using educational materials approved by the Medical Review Committee (MRC)
  • Draft, execute, monitor & adapt independent US MSL Stakeholder Engagement Plans for target KOLs/HCPs on an ongoing basis in alignment with the US Women’s Health MSL Team Lead and US Women’s Health Medical Lead
  • Receive support & direction for all normal asset-/disease state-level MSL business activities including all business travel, HCP interactions and congress attendance from US Women’s Health MSL Team Lead
  • Provide a summary of day-to-day activities & achievements on a monthly written basis to US Women’s Health MSL Team Lead
  • Submit expense reports and PTO/vacation requests in a timely manner
  • Document HCP Interactions in VEEVA
  • Respond with Reactive Medical Communications to Unsolicited Medical Requests (UMRs) received from HCPs or other external stakeholders
  • Identify & communicate internally the activities of rival Medical Affairs organizations with our target KOLs/HCPs
  • Identify & communicate internally the unmet medical education needs of our target KOLs/HCPs; share difficult concepts and negotiate with colleagues to adopt a different point of view
  • Partner with US Women’s Health MSL Team Lead and US Women’s Health Medical Lead to develop independent, new, innovative, nonpromotional, proactive and reactive medical education materials (eg, slide decks, videos) that differ from those provided by rival Medical Affairs organizations to uniquely address the unmet educational needs of our target KOLs/HCPs
  • Gather & communicate internally KOL insights related to independent US Medical and/or overarching company objectives or strategies to inform the advancement of independent US Medical and/or overarching company strategy
  • Develop & communicate internally independent Ad Board, Congress & Customer Insight Reports
  • Staff independent Medical Affairs booths at congresses/convention
  • Provide training to internal Viatris functions on products and disease states using materials approved by the MRC or the Viatris Promotional Material Approval Process (VMap) at the request of Commercial as appropriate
  • Perform other duties assigned

Viatris provides access to medicines worldwide with a portfolio of branded drugs, generics, complex generics, and biosimilars across 165+ countries. Medicines are manufactured and distributed through its global supply chain and commercial network, serving cardiovascular, infectious diseases, immunology, and oncology. It leverages the legacy of Mylan and Upjohn to grow through both expanding its existing products and pursuing partnerships and acquisitions, driven by its broad portfolio and international reach. The goal is to improve patient health by expanding access to affordable medicines while pursuing sustainable operations and addressing public health challenges like non-communicable diseases.

Company Size

10,001+

Company Stage

IPO

Headquarters

Canonsburg, Pennsylvania

Founded

1961

Simplify Jobs

Simplify's Take

What believers are saying

  • Q1 2026 revenue hits $3.52B, up 8.1%, driven by Greater China demand.
  • Projects 5-6% revenue CAGR through 2030 with $11B cash for deployments.
  • UBS upgrades to Buy with $18 target on Inpefa launches and cost savings.

What critics are saying

  • FDA Indore warning letter slashes stock 15% on February 27, 2025.
  • Pfizer biosimilar captures 35% EU Lipitor share, cutting $1.2B sales.
  • FTC probes Mylan pay-for-delay deals, imposing $2B fine by 2028.

What makes Viatris unique

  • Viatris leverages Mylan-Upjohn merger for global generics and biosimilars portfolio.
  • Dominates complex generics in cardiovascular and immunology across 165 countries.
  • Advances pipeline with selatogrel and cenerimod for long-term cardiology growth.

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at Viatris who can refer or advise you

Benefits

Health Insurance

Life Insurance

401(k) Retirement Plan

401(k) Company Match

Wellness Program

Paid Holidays

Company News

Yahoo Finance
Mar 23rd, 2026
Viatris shares surge 39.8% over past year, outpacing health care sector by 38.7%

Viatris, a global pharmaceutical company with a $15.2 billion market cap, has outperformed the broader healthcare sector despite recent headwinds. The Pennsylvania-based firm, which operates across 120 countries, has gained 39.8% over the past year, substantially ahead of the State Street Health Care Select Sector SPDR Fund's 1.1% decline. Shares have risen 10.7% over three months and 33.3% over six months, though they remain 19.9% below their 52-week high of $16.47. Viatris reported fourth-quarter revenue of $3.7 billion, up 5% year over year, with adjusted earnings per share of $0.57. Strong performance in branded drugs and emerging markets was offset by restructuring charges and pricing pressure in generics. Shares fell 5.2% following the announcement.

PR Newswire
Mar 23rd, 2026
Viatris wins approval for Effexor in Japan to treat generalised anxiety disorder

Viatris has received approval from Japan's Ministry of Health, Labour and Welfare for Effexor SR capsules to treat generalized anxiety disorder in adults, making it the first and only approved treatment for GAD in Japan. The drug was already approved in the country for major depressive disorder. The approval addresses a significant unmet need, as a recent study reported probable GAD prevalence of 7.6% in Japan's general population. The decision was based on a Phase 3 trial that demonstrated superior anxiolytic effects versus placebo at eight weeks, with all seven secondary endpoints met. Effexor was generally well tolerated with low discontinuation rates. Viatris' Japanese portfolio includes innovative products such as Spydia Nasal Spray, with several investigational therapies in development. Effexor is approved for GAD in over 80 countries worldwide.

PR Newswire
Mar 19th, 2026
Viatris targets $11B cash deployment through 2030 with 5-6% revenue growth

Viatris has outlined financial targets through 2030 at its investor event, projecting 5% to 6% total revenue compound annual growth and more than $3 billion in annual free cash flow by 2030. The pharmaceutical company's valuation at $1.45 billion reflects investor confidence in its strategic evolution. The Pittsburgh-based firm expects impactful near-term launches, including fast-acting meloxicam and a low-dose oestrogen patch in the US, alongside pitolisant and Effexor in Japan. Longer-term growth potential includes drug candidates selatogrel and cenerimod. Viatris anticipates over $11 billion in cash available for deployment through 2030, with approximately 50% allocated to business development. The company recently identified $650 million in cost savings over three years through an enterprise-wide strategic review.

Yahoo Finance
Mar 11th, 2026
Viatris shares surge 37.8% in six months, but analysts warn against buying despite cheap 5.8× P/E valuation

Viatris shares have surged 37.8% over the past six months, outpacing the S&P 500 by 34.7 percentage points, trading at $14.11. Despite the recent rally, analysts remain cautious about the pharmaceutical company's prospects. The company's fundamentals show concerning trends. Revenue grew at just 3.7% annually over the past five years, whilst earnings per share declined 9.8% annually during the same period, indicating deteriorating profitability. Most notably, Viatris posted a negative 2.6% five-year average return on invested capital, meaning management lost money whilst attempting business expansion. The stock currently trades at 5.8× forward price-to-earnings ratio. Analysts suggest the valuation appears optically cheap but warn of significant downside risk given the weak underlying fundamentals.

Yahoo Finance
Feb 26th, 2026
Viatris reports Q4 revenue of $3.7B, beating estimates by 5% with 10% growth in emerging markets

Viatris reported $3.7 billion in revenue for the quarter ended December 2025, representing a 5% year-over-year increase and beating the Zacks Consensus Estimate by 5.29%. Earnings per share reached $0.57, up from $0.54 a year ago and surpassing the consensus estimate of $0.52 by 9.62%. The pharmaceutical company showed strong performance across key segments. Greater China net sales rose 9.8% to $572.9 million, whilst Emerging Markets increased 10.1% to $564.7 million. Developed Markets generated $2.25 billion, up 4.7% year-over-year and exceeding analyst estimates. Shares of Viatris have gained 24% over the past month. The stock currently holds a Zacks Rank 3, suggesting it could perform in line with the broader market near term.